Explore the words cloud of the IPUD project. It provides you a very rough idea of what is the project "IPUD" about.
The following table provides information about the project.
PARAGATE MEDICAL LTD
|Coordinator Country||Israel [IL]|
|Total cost||2˙909˙785 €|
|EC max contribution||2˙036˙849 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-08-01 to 2021-07-31|
Take a look of project's partnership.
|1||PARAGATE MEDICAL LTD||IL (NAZARETH)||coordinator||2˙036˙849.00|
Pathologic fluid overload (congestion) is a medical condition when high volume of fluid (water) accumulates in the body leading to congestive heart failure (CHF). CHF is a severe global health problem affecting each year ~26 million people worldwide, of which 8 million are chronic and diuretic resistant patients. Current solutions for fluid overload in diuretic resistant patients such as infusion pump for intravenous (IV) diuresis, catheter-based device for ultrafiltration therapy and peritoneal dialysis all carry complications and are acute treatments which do not prevent recurrence. Paragate developed IPUD a unique implantable peritoneal ultrafiltration system for continuous monitoring and removal of extracellular fluids in CHF patients. It is minimally invasive (laparoscopic approach) and continuously (24/7) and slowly absorbs systemic isotonic extracellular fluid and drains it to the urinary system preventing recurred accumulation. In addition, IPUD guarantees a continuous monitoring of the fluid as well as the urinary system function thanks to a sensing system (embedded into the implantable system) and a treatment management platform. In this way, physicians have a direct control of the treatment and patient’s condition. The controlled, moderate non-aggressive fluid removal eliminates the main complications associated with the acute and aggressive treatments that lead to hemodynamic shock, worsening of renal function, arrhythmia and metabolic instability. Thanks to IPUD, patients will improve their quality of life eliminating frequent hospitalizations with a more effective treatment and healthcare systems will significantly reduce the €100 billion/year cost for frequent hospitalizations and treatment costs. The Phase 2 project will enable Paragate to scale-up production, perform validation and verification activities including a preclinical study; and validate the safety and efficacy of IPUD in a pilot clinical trial.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPUD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IPUD" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
IOT and cloud computing for online medical analysis service platformRead More
Carbon Offset Plug-inRead More